Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Jacqueline Vuky(Oregon Health & Science University), Elizabeth R. Plimack(Fox Chase Cancer Center), Peter H. O’Donnell(University of Chicago), Daniel Castellano(Universidad Complutense de Madrid), Petros Grivas(Seattle Cancer Care Alliance), Ronald de Wit(Erasmus MC Cancer Institute), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Arjun Vasant Balar(NYU Langone Health), Joaquim Bellmunt(Dana-Farber Cancer Institute), Blanca Homet Moreno(Merck & Co., Inc., Rahway, NJ, USA (United States)), Thomas Powles(Queen Mary University of London), Xiao Fang(Merck & Co., Inc., Rahway, NJ, USA (United States)), James Luke Godwin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Noah M. Hahn(Johns Hopkins University), Mary J. Savage(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tara L. Frenkl(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 292
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k